What can be expected from the Latin American pharmaceutical market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
Our 140-page report provides 121 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments.
See revenue forecasts for the leading international markets How will leading national markets perform to 2025? Our study forecasts revenues in national markets including by product class for the following countries: • Brazil • Mexico • Venezuela • Argentina • Colombia • Chile
Leading companies and potential for market growth Overall revenue for the Latin American pharmaceutical market will reach $87.29bn in 2018, our work forecasts. We predict strong revenue growth through to 2025. The ageing population in many of the region’s largest markets will combine with increasing investment in national health care systems to drive sales to 2025.
Our work analyses the key companies in the market. See Visiongain’s analysis of 5 leading companies, including these: • Sanofi • EMS • Novartis • Pfizer • Bayer
A company profile gives you the following information where available: • Historical revenues from 2013 to 2014 • Discussion of a company’s activities and outlook • Brief assessment of the companies Latin American strategy
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the Latin American pharmaceutical industry? Our new report discusses issues and events affecting the Latin American pharmaceutical market. You will find discussions, including qualitative analyses: • Highly diverse region needing strong knowledge of each national market • Quickly evolving regulatory environment • Economic weaknesses encouraging innovation
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Latin American Pharmaceutical Market Outlook 2015-2025 report helps you In summary, our 140-page report gives you the following knowledge: • Revenue forecasts to 2025 for the Latin American pharmaceutical market – discover the industry’s prospects, finding promising places for investments and revenues • Revenue forecasts to 2025 for the leading regional markets – Brazil, Mexico, Venezuela, Argentina, Colombia, Chile • Economic situation across the nations of Latin America – Understand the pressures faced across the region and how to achieve growth in an increasingly challenging environment • Assessment of 5 leading companies – analysis of Latin American results and strategies • Discussion of what stimulates and restrains companies and the market • Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Latin American Pharmaceutical market and leading companies. You find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Latin American Pharmaceutical Market: Overview 1.2 Latin American Pharmaceutical Market Segmentation 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Main Questions Answered by This Study 1.6 Who is This Investigation For? 1.7 Research and Analysis Methods 1.8 Frequently Asked Questions (FAQs) 1.9 Some Associated Reports 1.10 About Visiongain
2. Introduction to the Latin American Pharmaceutical Market 2.1 Introduction to the Global Pharmaceutical Market 2.2 The Latin American Pharmaceutical Market 2014 2.2.1 Definition of Latin America 2.3 Regional Trade Bodies and Intergovernmental Organisations 2.3.1 Mercado Comun del Sur/Mercado Comum do Sul (Mercosur) 2.3.2 The Andean Community (CAN) 2.3.3 The Union of South American Nations (USAN) 2.3.4 The Pacific Alliance 2.3.5 Bolivarian Alliance for the Peoples of Our America (ALBA)
3. The Latin American Pharmaceutical Market, 2015-2025 3.1 The Latin American Pharmaceutical Market Forecast, 2015-2025 3.2 Factors Affecting the Latin American Pharmaceutical Market 3.2.1 Population Growth and Ageing 3.2.2 Economic Conditions 3.2.3 Trans-Pacific Partnership (TPP) 3.3 The Latin American Pharmaceutical Market Breakdown, 2015-2025 3.3.1 The Latin American Generic Drugs Market Forecast, 2015-2025 3.3.2 The Latin American OTC Market Forecast, 2015-2025 3.3.3 The Latin American Biosimilars Market Forecast, 2015-2025 3.3.4 The Latin American Originator Drugs Market Forecast, 2015-2025 3.4 SWOT Analysis of the Latin American Pharmaceutical Market, 2015-2025 3.4.1 Strengths 3.4.1.1 One of the Quickest Growing Markets Globally 3.4.1.2 Increasing Incidence of Chronic Diseases 3.4.1.3 Ageing Population 3.4.1.4 Increasing Investment in Health Care Systems 3.4.2 Weaknesses 3.4.2.1 Poor Economic Performance and Devalued Currencies 3.4.2.2 Weak Regulation 3.4.2.3 Weak IP Protection 3.4.3 Opportunities 3.4.3.1 Emerging Biosimilars Market 3.4.3.2 Regional Pharmaceutical Companies Could Expand Outside Latin America 3.4.3.3 Increased Trade Liberalisation Could Open More Markets 3.4.4 Threats 3.4.4.1 Pharmaceutical Companies from Other Emerging Markets Could Challenge Regional Firms 3.4.4.2 Increased Protectionist Measures Could Severely Harm the Industry 3.4.4.3 Further Economic Problems and Currency Devaluations Possible
4. Latin American National Markets, 2015-2025 4.1 Latin American National Markets, 2014 4.2 Latin American National Pharmaceutical Market Forecasts, 2015-2025 4.3 Leading National Markets as Shares of the Latin American Pharmaceutical Market 4.3.1 Leading National Markets as Shares of the Latin American Pharmaceutical Market, 2014 4.3.2 Leading National Markets as Shares of the Latin American Pharmaceutical Market, 2020 4.3.3 Leading National Markets as Shares of the Latin American Pharmaceutical Market, 2025
5. The Brazilian National Pharmaceutical Market, 2015-2025 5.1 The Brazilian National Pharmaceutical Market, 2014 5.2 The Brazilian National Pharmaceutical Sub-Market Forecasts, 2015-2025 5.2.1 The Brazilian National Pharmaceutical Market Forecast, 2015-2025 5.2.2 The Brazilian Generic Drugs Market Forecast, 2015-2025 5.2.3 The Brazilian OTC Market Forecast, 2015-2025 5.2.4 The Brazilian Biosimilars Market Forecast, 2015-2025 5.2.5 The Brazilian Originator Drugs Market Forecast, 2015-2025 5.3 The Brazilian National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations
6. The Mexican National Pharmaceutical Market, 2015-2025 6.1 The Mexican National Pharmaceutical Market, 2014 6.2 The Mexican National Pharmaceutical Sub-Markets Forecasts, 2015-2025 6.2.1 The Mexican National Pharmaceutical Market Forecast, 2015-2025 6.2.2 The Mexican Generic Drugs Market Forecast, 2015-2025 6.2.3 The Mexican OTC Market Forecast, 2015-2025 6.2.4 The Mexican Biosimilars Market Forecast, 2015-2025 6.2.5 The Mexican Originator Drugs Market Forecast, 2015-2025 6.3 The Mexican National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations
7. The Venezuelan National Pharmaceutical Market, 2015-2025 7.1 The Venezuelan National Pharmaceutical Market, 2014 7.2 The Venezuelan National Pharmaceutical Market Breakdown Forecast, 2015-2025 7.2.1 The Venezuelan National Pharmaceutical Market Forecast, 2015-2025 7.2.2 The Venezuelan Generic Drugs Market Forecast, 2015-2025 7.2.3 The Venezuelan OTC Market Forecast, 2015-2025 7.2.4 The Venezuelan Biosimilars Market Forecast, 2015-2025 7.2.5 The Venezuelan Originator Drugs Market Forecast, 2015-2025 7.3 The Venezuelan National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations
8. The Argentine National Pharmaceutical Market, 2015-2025 8.1 The Argentine National Pharmaceutical Market, 2014 8.2 The Argentine National Pharmaceutical Market Breakdown, 2015-2025 8.2.1 The Argentine National Pharmaceutical Market Forecast, 2015-2025 8.2.2 The Argentine Generic Drugs Market Forecast, 2015-2025 8.2.3 The Argentine OTC Market Forecast, 2015-2025 8.2.4 The Argentine Biosimilars Market Forecast, 2015-2025 8.2.5 The Argentine Originator Drugs Market Forecast, 2015-2025 8.3 The Argentine National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations
9. The Colombian National Pharmaceutical Market, 2015-2025 9.1 The Colombian National Pharmaceutical Market, 2014 9.2 The Colombian National Pharmaceutical Market Breakdown, 2015-2025 9.2.1 The Colombian National Pharmaceutical Market Forecast, 2015-2025 9.2.1.1 Economic Growth and Financial Constraints 9.2.1.2 Introduction of the Statutory Health Law 9.2.2 The Colombian Generic Drugs Market Forecast, 2015-2025 9.2.3 The Colombian OTC Market Forecast, 2015-2025 9.2.4 The Colombian Biosimilars Market Forecast, 2015-2025 9.2.5 The Colombian Originator Drugs Market Forecast, 2015-2025 9.3 The Colombian National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations
10. The Chilean National Pharmaceutical Market, 2015-2025 10.1 The Chilean National Pharmaceutical Market, 2014 10.1.1 The Chilean Health Care System 10.1.2 Majority of Generic Revenue from Branded Generics 10.2 The Chilean National Pharmaceutical Market Breakdown, 2015-2025 10.2.1 The Chilean National Pharmaceutical Market Forecast, 2015-2025 10.2.2 The Chilean Generic Drugs Market Forecast, 2015-2025 10.2.3 The Chilean OTC Market Forecast, 2015-2025 10.2.4 The Chilean Biosimilars Market Forecast, 2015-2025 10.2.5 The Chilean Originator Drugs Market Forecast, 2015-2025 10.3 The Chilean National Pharmaceutical Sub-Market Forecasts Accounting for Current Currency Fluctuations
11. The Rest of the Latin American Pharmaceutical Market, 2015-2025 11.1 The Rest of the Latin American Pharmaceutical Market, 2014 11.2 The Rest of the Latin American Pharmaceutical Market Breakdown, 2015-2025 11.2.1 The Rest of the Latin American Pharmaceutical Market Forecast, 2015-2025 11.2.2 The Rest of the Latin American Generic Drugs Market Forecast, 2015-2025 11.2.3 The Rest of the Latin American OTC Market Forecast, 2015-2025 11.2.4 The Rest of the Latin American Biosimilars Market Forecast, 2015-2025 11.2.5 The Rest of the Latin American Originator Drugs Market Forecast, 2015-2025 11.3 Accounting for Currency Fluctuations in the Rest of Latin America
12. Top Five Pharmaceutical Companies in Latin America 12.1 Sanofi S.A 12.2 EMS S.A 12.3 Novarits 12.4 Pfizer 12.5 Bayer
13. Conclusions 13.1 The Latin American Pharmaceutical Market, 2014-2025 13.2 Latin American Pharmaceutical Market Forecast, 2015-2025
List of Tables Table 2.1 Market Share (%) of the Global Pharmaceutical Market by Region, 2014 Table 2.2 Population Sizes of Latin American Countries/Regions and Percentage of Total Population (%), 2012 Table 3.1 The Latin American Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025 Table 3.2 Percentage (%) of Population Over 65 Years Old in Key Latin American Markets, plus Average, 2010 and 2050 Table 3.3 The Latin American Pharmaceutical Market Breakdown, Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 3.4 The Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 3.5 The Latin American OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 3.6 The Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 3.7 The Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 3.8 SWOT Analysis of the Latin American Pharmaceutical Market, 2014-2025 Table 4.1 Market Revenues ($bn) of the Six Largest Pharmaceutical Markets in Latin America, 2014 Table 4.2 The Latin American National Pharmaceutical Markets: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025 Table 4.3 National Market Revenues ($bn) and Latin American Market Shares (%), 2014 Table 4.4 National Market Revenues ($bn) and Latin American Market Shares (%), 2020 Table 4.5 National Market Revenues ($bn) and Latin American Market Shares (%), 2025 Table 5.1 Brazilian National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 5.2 Brazilian National Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 5.3 Brazilian Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 5.4 Brazilian OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 5.5 Brazilian Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 5.6 Brazilian Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 5.7 Brazilian National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.1 Mexican National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.2 Mexican National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.3 Mexican Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.4 Mexican OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.5 Mexican Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.6 Mexican Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 6.7 Mexican National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 7.1 Venezuelan National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 7.2 Venezuelan National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 7.3 Venezuelan Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 7.4 Venezuelan OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 7.5 Venezuelan Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 7.6 Venezuelan Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 8.1 Argentine National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 8.2 Argentine National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 8.3 Argentine Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 8.4 Argentine OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 8.5 Argentine Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 8.6 Argentine Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 8.7 Argentine National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 9.1 Colombian National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 9.2 Colombian National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 9.3 Colombian Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 9.4 Colombian OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 9.5 Colombian Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 9.6 Colombian Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 9.7 Colombian National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 10.1 Branded Market Share (%) of Generic Drugs Market by Value, 2014 Table 10.2 Chilean National Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 10.3 Chilean National Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 10.4 Chilean Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 10.5 Chilean OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 10.6 Chilean Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 10.7 Chilean Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 10.8 Chilean National Market Breakdown: Revenue (Currency Adjusted) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 11.1 The Rest of the Latin American Pharmaceutical Market Breakdown: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 11.2 Rest of the Latin American Pharmaceutical Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 11.3 Rest of the Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 11.4 Rest of the Latin American OTC Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 11.5 Rest of the Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 11.6 Rest of the Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn), AGR (%) and CAGR (%), 2014-2025 Table 12.1 Sanofi S.A Total Revenue ($bn) and Latin American Revenue ($bn) and AGR (%), 2013-2014 Table 12.2 Novartis Total Revenue ($bn) and Latin American Revenue ($bn) and AGR (%), 2013-2014 Table 13.1 The Latin American National Pharmaceutical Markets: Revenue ($bn), AGR (%), 2014-2015 Table 13.2 The Latin American Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%), 2014-2025
List of Figures Figure 1.1 Population Sizes of Latin American Countries/Regions by Percentage (%), 2013 Figure 1.2 Key Markets within the Latin American Pharmaceutical Market Figure 1.3 Key Product Types within the Latin American Pharmaceutical Market Figure 2.1 Market Shares (%) of Pharmaceutical Market by Region, 2014 Figure 2.2 Population Sizes of Latin American Countries/Regions by Percentage (%), 2012 Figure 3.1The Latin American Pharmaceutical Market: Revenue ($bn) and AGR (%), 2014-2025 Figure 3.2 Population Pyramid for Latin America, 2010 Figure 3.3 Population Pyramid for Latin America, 2025 Figure 3.4 The Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 3.5 The Latin American OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 3.6 The Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 3.7 The Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 4.1 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2014 Figure 4.2 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2014 Figure 4.3 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2020 Figure 4.4 Market Revenues ($bn) of Six Largest Pharmaceutical Markets in Latin America plus Rest of Latin America, 2025 Figure 5.1 Brazilian National Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 5.2 Brazilian Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 5.3 Brazilian OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 5.4 Brazilian Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 5.5 Brazilian Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 6.1 Mexican National Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 6.2 Mexican Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 6.3 Mexican OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 6.4 Mexican Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 6.5 Mexican Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 7.1 Venezuelan National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 7.2 Venezuelan Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 7.3 Venezuelan OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 7.4 Venezuelan Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 7.5 Venezuelan Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 8.1 Argentine National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 8.2 Argentine Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 8.3 Argentine OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 8.4 Argentine Biosimilars Market: Revenue (Constant Currencies) $bn) and AGR (%), 2014-2025 Figure 8.5 Argentine Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 9.1 Colombian National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 9.2 Colombian Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 9.3 Colombian OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 9.4 Colombian Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 9.5 Colombian Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 10.1 Branded Market Share (%) of Generic Drugs Market by Value, 2014 Figure 10.2 Chilean National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 10.3 Chilean Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 10.4 Chilean OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 10.5 Chilean Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 10.6 Chilean Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 11.1 Rest of the Latin American National Pharmaceutical Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 11.2 Rest of the Latin American Generic Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 11.3 Rest of the Latin American OTC Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 11.4 Rest of the Latin American Biosimilars Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 11.5 Rest of the Latin American Originator Drugs Market: Revenue (Constant Currencies) ($bn) and AGR (%), 2014-2025 Figure 13.1 The Latin American National Pharmaceutical Markets: Revenue ($bn), 2014-2015 Figure 13.2 The Latin American Pharmaceutical Market: Revenue ($bn), 2014-2025
Other Organisations Mentioned In The Report Bolivarian Alliance for the Peoples of Our America (ALBA) Brazilian Ministry of Health Brazilian Unified Health System Chilean Institute of Public Health COFEPRIS Instituto de Seguridad y Servicios Sociales de los Trabajadoes del Estad (ISSSTE) Instituto Mexicano del Seguro Social (IMSS) Instituto Venezolano de los Seguros Sociales (IVSS) Mercosur National Drugs Agency (ANAMED) Pan American Health Organisation Sistema General de Seguridad Social en Salud The Andean Community (CAN) The Pacific Alliance The Union of South American Nations (USAN) Trans-Pacific Partnership United Nations Department of Economic and Social Affairs Venezuelan Ministry of Popular Power for Health
Download sample pages
Complete the form below to download your free sample pages for Latin American Pharmaceutical Market Outlook 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Latin American Pharmaceutical Market Outlook 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
